Log in

Relevant bibliographies by topics / Grazoprevir

Contents

Journal articles
Book chapters
Conference papers
Reports

Academic literature on the topic 'Grazoprevir'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Grazoprevir.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Grazoprevir"

1

Seetharamaiah, P., Nagaraju Pappula, G. Poornima, and G. Chandanashree. "Development and Validation of new RP-HPLC Method for the Simultaneous Estimation of Elbasvir and Grazoprevir in Combined Pharmaceutical Dosage Form." Journal of Pharmaceutical Research 22, no. 3 (2023): 172–77. http://dx.doi.org/10.18579/jopcr/v22.3.22.6.

Full text

Abstract:

A reliable and exact technique was formulated for concurrently determining Elbasvir and Grazoprevir in tablet dosage forms. Chromatogram was developed by running a sample through Zodiac C18 column (4.6 x 150 mm, 5 µm) with the mobile phase containing Orthophosphoric acid (0.1%) and Acetonitrile in the ratio 50:50 v/v. The solution was pumped through the column at a flow rate of 1 ml/min, while maintaining the column temperature at 30°C. The optimized wavelength selected was 260 nm. The retention times for Elbasvir and Grazoprevir were determined to be 2.32 min and 3.30 min, respectively. The p

APA, Harvard, Vancouver, ISO, and other styles

2

Lahser, Frederick C., Karin Bystol, Stephanie Curry, et al. "The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons." Antimicrobial Agents and Chemotherapy 60, no. 5 (2016): 2954–64. http://dx.doi.org/10.1128/aac.00051-16.

Full text

Abstract:

ABSTRACTThe selection of resistance-associated variants (RAVs) against single agents administered to patients chronically infected with hepatitis C virus (HCV) necessitates that direct-acting antiviral agents (DAAs) targeting multiple viral proteins be developed to overcome failure resulting from emergence of resistance. The combination of grazoprevir (formerly MK-5172), an NS3/4A protease inhibitor, and elbasvir (formerly MK-8742), an NS5A inhibitor, was therefore studied in genotype 1a (GT1a) replicon cells. Both compounds were independently highly potent in GT1a wild-type replicon cells, wi

APA, Harvard, Vancouver, ISO, and other styles

3

Pijnenburg, Daniëlle W. M., Minou van Seyen, Evertine J. Abbink, Angela Colbers, Joost P. H. Drenth, and David M. Burger. "Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection." Journal of Antimicrobial Chemotherapy 75, no. 9 (2020): 2661–65. http://dx.doi.org/10.1093/jac/dkaa230.

Full text

Abstract:

Abstract Background Finding a suitable treatment for HCV patients with swallowing disorders is still a major challenge. In practice, direct-acting antivirals are crushed without knowledge of adequate absorption. Crushing can alter drug exposure, possibly leading to treatment failure, development of resistance or toxicity. Currently, there is no information about crushing of the fixed-dose combination tablet of elbasvir/grazoprevir; therefore, crushing of this tablet is not recommended. Objectives To investigate the influence of crushing on the pharmacokinetics of the elbasvir/grazoprevir fixed

APA, Harvard, Vancouver, ISO, and other styles

4

Cada, Dennis J., Anne P. Kim, and Danial E. Baker. "Elbasvir/Grazoprevir." Hospital Pharmacy 51, no. 8 (2016): 665–86. http://dx.doi.org/10.1310/hpj5108-665.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Pallapati, Suman1 2* Tirukkovalluri Siva Rao1 Kallam Venkata Siva Rama Krishna Reddy2. "HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF ANTIVIRAL DRUGS, GRAZOPREVIR AND ELBASVIR, SIMULTANEOUSLY IN BULK AND IN TABLETS." INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH 07, no. 09 (2017): 464–70. https://doi.org/10.5281/zenodo.1036470.

Full text

Abstract:

The current investigation described a sensitive, selective, precise and accurate RP-HPLC method with photodiode array detector for the simultaneous estimation of antiviral drugs, grazoprevir and elbasvir. The separation and analysis were done on Sunsil C18 analytical column (250 mm x 4.6 mm, 5 μ particle size). 0.1M NaH2PO4: methanol [60:40 v/v] in isocratic elution mode was used as mobile phase. The pH of the mobile was adjusted to 4.0 with orthophosphoric acid. The elution of grazoprevir and elbasvir was accomplished with a flow rate of 1.2 ml/min. Detection was performed with photodiode arr

APA, Harvard, Vancouver, ISO, and other styles

6

Kumar, V. Pavan, A. Vijaya Kumar, B. Sivagami, R. Charan Kumar, and M. Niranjan Babu. "Stability indicating RP-HPLC method development and validation for the simultaneous estimation of Grazoprevir and Elbasvir in bulk and pharmaceutical dosage form." International Journal of Research In Pharmaceutical Chemistry and Analysis 1, no. 1 (2018): 1–7. http://dx.doi.org/10.33974/ijrpca.v1i1.4.

Full text

Abstract:

A simple, Accurate and precise method was developed for the simultaneous estimation of the Grazoprevir and Elbasvir in Tablet dosage form. Chromatogram was run through Kromosil C18 (250 x 4.6 mm), 5m. Mobile phase containing Buffer: Acetonitrile taken in the ratio 45:55 was pumped through column at a flow rate of 1 ml/min. Buffer used in this method was Di Potassium Hydrogen ortho Phosphate. Temperature was maintained at 30°C. Optimized wavelength selected was 215 nm. Retention time of Elbasvir and Grazoprevir and were found to be 2.503 min and 3.004. %RSD of the Elbasvir and Grazoprevir were

APA, Harvard, Vancouver, ISO, and other styles

7

Guo, Zifang, Luzelena Caro, Michael N. Robertson, et al. "The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevir." Pharmacogenomics 20, no. 9 (2019): 631–41. http://dx.doi.org/10.2217/pgs-2019-0022.

Full text

Abstract:

Aim: To evaluate the effect of SLCO1B1 genetic variants on grazoprevir pharmacokinetics and efficacy. Methods: A retrospective analysis of 1578 hepatitis C virus-infected participants from ten Phase II/III clinical trials. Results: Relative to noncarriers of the risk allele, geometric mean ratios (95% CI) of grazoprevir area under curve (AUC)0–24 were: rs4149056 (risk allele C), one copy, 1.13 (1.06–1.21), two copies, 1.43 (1.16–1.77); and rs11045819 (risk allele A), one copy, 0.93 (0.87–1.00); two copies, 0.78 (0.61–1.00). The rs2306283 variant was not associated with grazoprevir exposure. No

APA, Harvard, Vancouver, ISO, and other styles

8

Swapna.Goday*, S.K.Abdul Rahaman A.Prameelarani. "FORCED DEGRADATION STUDIES DEVELOPMENT AND VALIDATION BY RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF COMBINATION DRUGS ELBASVIR AND GRAZOPREVIR IN BULK AND PHARMACEUTICAL DOSAGE FORMS." Indo American Journal of Pharmaceutical Sciences 04, no. 08 (2017): 2526–33. https://doi.org/10.5281/zenodo.848507.

Full text

Abstract:

A Stability-indicating reverse phase – high performance liquid chromatography(RP-HPLC) method was developed and validated for the determination of Elbasvir and Grazoprevir in tablet dosage forms using C18 column Discovery( 250x4.6 mm, 5 µ) with a mobile phase consisting of orthophosphoric acid and methanol (45:55% v/v). The pH was adjusted to 3.8 with dil. NaoH.The mobile phase was sonicated for 10min and filtered through a 0.45µm membrane filter at a flow rate of 1.0 ml/min.The Detection was carried out at 220nm and retention time of Grazoprevir was found to be 2.3min ,and retention time of E

APA, Harvard, Vancouver, ISO, and other styles

9

Yao, Yinan, Ming Yue, Jie Wang, et al. "Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis." Canadian Journal of Gastroenterology and Hepatology 2017 (2017): 1–7. http://dx.doi.org/10.1155/2017/8186275.

Full text

Abstract:

Background. It is urgent for patients with hepatitis C virus (HCV) infection to find a safe, effective, and interferon-free regimen to optimize therapy. A comprehensive analysis was performed to evaluate the efficacy and safety of the grazoprevir combined with elbasvir, with or without ribavirin (RBV), in 777 treatment-naive and treatment-experienced patients with HCV genotype 1 infection from 3 randomized controlled trials (RCTs). Method. We collected data from the following trials: C-WORTHY (NCT01717326), C-SALVAGE (NCT02105454), and C-EDGE (NCT02105467). All patients received grazoprevir pl

APA, Harvard, Vancouver, ISO, and other styles

10

Srisailam, Nakka, Narmada Vallakeerthi, Revathy Sundara Moorthy, and Kavitha Marapakala. "Simultaneous RP-HPLC Estimation, Validation and Stability Indicating Assay of Two-Component Tablet Formulation Containing Grazoprevir and Pibrentasvir." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 15, no. 02 (2024): 895–900. http://dx.doi.org/10.25258/ijpqa.15.2.55.

Full text

Abstract:

The determination of a two-component tablet formulation containing grazoprevir and pibrentasvir for method development and validation has been done using the reverse-phase high-performance liquid chromatography (RP-HPLC) method as per International Council of Harmonization (ICH) guidelines. Analytical grade acetonitrile and 0.01 N of potassium dihydrogen phosphate buffer were used as mobile phase while Kromasil C18 column was opted for separation. In order to elute the analyte a flow rate of 1-mL/min having 260 nm λ has been maintained. An RT of 2.909 and 2.358 minutes while linearity concentr

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Grazoprevir"

1

McCauley, John A., and Michael T. Rudd. "The Invention of Grazoprevir: An HCV NS3/4a Protease Inhibitor." In Topics in Medicinal Chemistry. Springer International Publishing, 2019. http://dx.doi.org/10.1007/7355_2018_41.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Xu, Feng, and John A. McCauley. "Discovery and Chemical Development of Grazoprevir: An HCV NS3/4a Protease Inhibitor for the Treatment of the Hepatitis C Virus Infection." In ACS Symposium Series. American Chemical Society, 2020. http://dx.doi.org/10.1021/bk-2020-1369.ch009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

"ZEPATIER (Elbasvir and Grazoprevir)." In Antibiotics Manual. John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119220787.ch200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Somayana, Gde, and Komang Agus Wira Nugraha. "Chronic Hepatitis C Virus Infection in Chronic Kidney Disease." In Hepatitis C - Recent Advances [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.1001052.

Full text

Abstract:

Chronic Hepatitis C virus (HCV) infection in chronic kidney disease (CKD) patients can accelerate the decline of kidney function, increase the risk of kidney failure, and increase mortality in CKD patients on hemodialysis (HD). Chronic HCV infection is also a risk factor of mortality in kidney transplant patients. Effective detection, evaluation and treatment for HCV infection can improve kidney and cardiovascular outcomes. In the subsequent 10 years, direct-acting antivirals (DAAs) has become available. DAAs enabled a greater rate of HCV eradication in CKD populations. Patients with stage 1-3

APA, Harvard, Vancouver, ISO, and other styles

5

Bhangale, Charushila, Sachin Somwanshi, Kiran Kotade, and Mayur Gaikar. "QbD Approach to Stability Indicating HPLC Method for Estimation of Elbasvir and Grazoprevir by Green Assessment Method." In Pharmaceutical Science: New Insights and Developments Vol. 2. BP International, 2025. https://doi.org/10.9734/bpi/psnid/v2/4074.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Padmavathi, Sakinala, Sk Abdul Rahaman, Swapna Gaday, Kameswara Rao Sankula, and Durga Bhavani Pendeti. "Recent Development and Validation of RP-HPLC Method for Simultaneous Estimation of Grazoprevir and Elbasvir in Bulk and Pharmaceutical Dosage Form." In Technological Innovation in Pharmaceutical Research Vol. 3. Book Publisher International (a part of SCIENCEDOMAIN International), 2021. http://dx.doi.org/10.9734/bpi/tipr/v3/8281d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Grazoprevir"

1

Mensa, M., JM Sotoca, and C. Codina. "4CPS-096 Effectiveness, safety and potential interactions of elbasvir/grazoprevir for chronic hepatitis c infection." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.187.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Schattenberg, J., A. Stoehr, M. Cornberg, et al. "Real-world efficacy of elbasvir/grazoprevir in HCV GT1 infected diabetics: results from the German Hepatitis C Registry." In 36. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-3402279.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Stein, K., A. Böhlig, A. Stoehr, et al. "Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease - Data from the German Hepatitis C-Registry (DHC-R)." In DGVS Digital: BEST OF DGVS. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1716035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hinrichsen, H., A. Stoehr, M. Cornberg, et al. "High effectiveness of elbasvir/grazoprevir (EBR/GZR) treatment in patients with HCV genotype 1a (GT1a) infection in German real-world: results from the German Hepatitis C Registry (DHC-R)." In Viszeralmedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1695337.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hinrichsen, H., H. Klinker, A. Stoehr, et al. "High real-world efficacy of elbasvir/grazoprevir (EBR/GZR) in genotype 1 (GT1) infected patients with and without liver cirrhosis: results from the German Hepatitis C Registry (DHC-R)." In 35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0038-1677260.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Christensen, S., A. Stoehr, M. Cornberg, et al. "High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in PWID on opioid substitution therapy with HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)." In Viszeralmedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1695339.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hüppe, D., A. Stoehr, M. Cornberg, et al. "High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in a HCV genotype 1 (GT1) population with a migration background and predominant subtype 1b infection: results from the German Hepatitis C Registry (DHC-R)." In Viszeralmedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1695338.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Grazoprevir"

1

Hung, Hsuan-Yu, Hui-Hsiung Lai, Hui-Chuan Lin, and Chung-Yu Chen. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0055.

Full text

Abstract:

Review question / Objective: P: ("Hepatitis C"[Mesh] AND "Hepacivirus"[Mesh] AND "Hepatitis C, Chronic”[Mesh]) I: (direct acting antiviral OR asunaprevir OR boceprevir OR daclatasvir OR dasabuvir OR elbasvir OR glecaprevir OR grazoprevir OR ledipasvir OR ombitasvir OR paritaprevir OR pibrentasvir OR simeprevir OR sofosbuvir OR telaprevir OR velpatasvir OR voxilaprevir) C: placebo O: ( "Cholesterol, VLDL"[Mesh] OR "Cholesterol, LDL"[Mesh] OR "Cholesterol, HDL"[Mesh] OR "Dyslipidemias"[Mesh] OR "lipoprotein cholesterol ester, human" [Supplementary Concept] OR "lipoprotein cholesterol" [Supplemen

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!